Wedbush Upgrades NeurogesX, Inc. (NGSX) to Outperform; Restructuring Puts NGX-1998 Liquid Formulation On Center Stage

March 14, 2012 1:50 PM EDT
Get Alerts NGSX Hot Sheet
Price: $0.01 --0%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 19 | New: 6
Join SI Premium – FREE
Wedbush upgraded NeurogesX, Inc. (NASDAQ: NGSX) from Neutral to Outperform with a price target of $2.00.

Wedbush analyst said, "We believe that there is little downside for NGSX shares at current levels given the recently announced restructuring, current cash and renewed focus on NGX-1998. NGX-1998, a liquid topical formulation prescription strength capsaicin product, offers several benefits over QUTENZA and as a follow-on product has a high chance of clinical and regulatory success."

Wedbush raises FY12 EPS loss from (1.78) to (0.59)

For an analyst ratings summary and ratings history on NeurogesX, Inc. click here. For more ratings news on NeurogesX, Inc. click here.

Shares of NeurogesX, Inc. closed at $0.48 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst EPS Change, Analyst EPS View, Upgrades